Investigating how a specific stress response affects pain in diabetes
Official title: Targeting methylglyoxal-induced diabetic neuropathic pain through the integrated stress response
Funded at University of Texas Dallas · NIH-10923791 · Data updated 2026-11-12
This study is looking at how a substance called methylglyoxal, which is produced when your body makes energy, might be causing extra pain for people with diabetes, and it hopes to find new ways to help ease that pain and improve daily life for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project start | September 7, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $608,698 |
| NIH project number | 5R01DK134893-02 |
| Project ID | NIH-10923791 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with diabetes who experience chronic neuropathic pain.
✕Less likely to help
Patients without diabetes or those who do not experience neuropathic pain may not benefit from this research.
What this research studies
This research focuses on understanding the role of methylglyoxal, a by-product of energy production, in causing chronic pain associated with diabetes. It explores how this compound triggers a stress response in nerve cells, leading to increased pain sensitivity. By studying both animal models and human sensory neurons, the research aims to identify potential therapeutic targets to alleviate diabetic neuropathic pain. The ultimate goal is to develop new treatment strategies that can improve the quality of life for individuals suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce chronic pain in diabetic patients.
How similar studies have gone: Previous research has shown promising results in targeting stress responses for pain management, suggesting potential success for this approach.
Where this research is happening
-
University of Texas Dallas
Richardson, United States Active
Researchers
- Principal investigator: Yousuf, Muhammad Saad — University of Texas Dallas
- Study coordinator: Yousuf, Muhammad Saad
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Parmodulins with Low Abuse Potential for Neuropathic Pain
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.